Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUIDIL (cyclothiazide) is an oral thiazide diuretic tablet in pre-launch development by Pfizer. Cyclothiazide is a small-molecule diuretic used primarily for hypertension and edema management. The mechanism involves inhibition of sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion.
Pre-Launch
Pre-launch stage offers opportunity to build foundational commercial infrastructure; team size will scale post-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch product offers early-career visibility into launch planning and regulatory execution at Pfizer. Joining the FLUIDIL team now positions you to influence go-to-market strategy and build portfolio ownership before peak commercialization.
Regulatory Affairs SpecialistBrand Manager
Worked on FLUIDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.